Assessment of miR-21 and miR-122 gene expression and AFP, DCP, and GPC3 protein levels as diagnostic biomarkers in hepatocellular carcinoma
DOI:
https://doi.org/10.31185/bsj.Vol23.Iss46.1876Keywords:
: Hepatocellular carcinoma, diagnostic biomarkers, miR-122, and miR-21.Abstract
The most common type of liver cancer is hepatocellular carcinoma (HCC), which typically occurs in people with chronic liver disease caused by infection with hepatitis viruses or cirrhosis. Diagnostic issues of HCC and evaluation of therapeutic efficacy are large challenges. The aim of this study is to explore the clinical significance of AFP, DCP, GPC3, miR-21, and miR-122 in early detection of hepatocellular carcinoma (HCC) and their role in monitoring therapeutic responses. A total of 180 participants were selected and divided into three groups; treated HCC patients (60 persons), untreated HCC patients (60 persons) and healthy controls (60 persons). AFP, DCP, and GPC3 were quantified in the serum by ELISA method and the expression of miR-21 and miR-122 by q-RT-PCR. Results showed that miRNA-21, AFP, DCP, and GPC3 were significantly higher in HCC patients, and miR-122 was significantly lower in HCC patients compared to controls. The outcomes also demonstrate that the treated group differs noticeably from the untreated group. Results suggest that miRNA-21, miR-122, AFP, DCP, and GPC3 could be important biomarkers for the diagnosis of HCC and evaluation of response to therapy.
References
References
1. Al-Gazally, M. E., Khan, R., Imran, M., Ramírez-Coronel, A. A., Alshahrani, S. H., Altalbawy, F. M. A., Jalil, A. T., Romero-Parra, R. M., Zabibah, R. S., Iqbal, M. S., Karampoor, S.,&Mirzaei, R. (2023). The role and mechanism of action of microRNA-122 in cancer: Focusing on the liver. International Immunopharmacology,123,Article110713.DOI:10.1016/j.intimp.2023.110713.
2. Alaee, M., Moulaee, M., Taebi, K., Haghi, A., Hormozi, M.,&Azad, M. (2026). The role of miRNA-21 in the metastasis of hepatocellular carcinoma as a therapeutic target. International Journal of Hematology-Oncology and Stem Cell Research, 20(1). DOI: 10.18502/ijhoscr.v20i1.14486.
3. Ascha, M. S., Hanouneh, I. A., Lopez, R., Tamimi, T. A. R., Feldstein, A. F.,&Zein, N. N. (2010). The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology, 51(6), 1972–1978. DOI: 10.1002/hep.23527.
4. Bandiera, S., Pfeffer, S., Baumert, T. F.,&Zeisel, M. B. (2015). miR-122—A key factor and therapeutic target in liver disease. Journal of Hepatology, 62(2), 448–457. DOI: 10.1016/j.jhep.2014.10.004.
5. Capurro, M., Wanless, I. R., Sherman, M., Deboer, W., Shi, W., Miyoshi, E., & Filmus, J. (2003). Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology, 125(1), 89–97.DOI: 10.1016/S0016-5085(03)00690-3.
6. Charrière, B., Maulat, C., Suc, B., & Muscari, F. (2016). Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma. World Journal of Hepatology, 8(21), 881–890. DOI: 10.4254/wjh.v8.i21.881.
7. Chun, K. H. (2022). Molecular targets and signaling pathways of microRNA-122 in hepatocellular carcinoma. Pharmaceutics, 14(7), Article 1380. DOI: 10.3390/pharmaceutics14071380.
8. Di Carlo, I., Mannino, M., Toro, A., Ardiri, A., Galia, A., Cappello, G., & Bertino, G. (2012). Persistent increase in alpha-fetoprotein level in a patient without underlying liver disease who underwent curative resection of hepatocellular carcinoma: A case report and review of the literature. World Journal of Surgical Oncology, 10, Article 52. DOI: 10.1186/1477-7819-10-52.
9. Farazi, T. A., Hoell, J. I., Morozov, P., & Tuschl, T. (2012). MicroRNAs in human cancer. In MicroRNA Cancer Regulation: Advanced Concepts, Bioinformatics and Systems Biology Tools (pp. 1–20). Springer. DOI: 10.1007/978-94-007-5590-1_1.
10. Gao, J., Feng, X., Inagaki, Y., Song, P., Kokudo, N., Hasegawa, K., ...&Tang, W. (2012). Des-γ-carboxy prothrombin and c-Met were concurrently and extensively expressed in hepatocellular carcinoma and associated with tumor recurrence. Bioscience Trends, 6(4), 153–159. DOI: 10.5582/bst.2012.v6.4.153.
11. Guo, X., Lv, X., Ma, X., Chen, L.,&Chen, Y. (2017). Circulating miR-21 serves as a serum biomarker for hepatocellular carcinoma and is correlated with distant metastasis. Oncotarget, 8(27), 44050–44058. DOI: 10.18632/oncotarget.16823.
12. Hu, X., Chen, R., Wei, Q.,&Xu, X. (2022). The landscape of alpha fetoprotein in hepatocellular carcinoma: Where are we?. International Journal of Biological Sciences, 18(2), 536–547. DOI: 10.7150/ijbs.64537.
13. Huang, C. S., Yu, W., Cui, H., Wang, Y. J., Zhang, L., Han, F., & Huang, T. (2015). Increased expression of miR-21 predicts poor prognosis in patients with hepatocellular carcinoma. International Journal of Clinical and Experimental Pathology, 8(6), 7234–7240. DOI: 10.26261571.
14. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011). Global cancer statistics. CA: A Cancer Journal for Clinicians, 61(2), 69–90. DOI: 10.3322/caac.20107.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 م.د. : احلام حميد مجيد جامعه واسط كلية العلوم قسم الادلة الجنائية، م.م. ريام معين عبد جامعه واسط /كلية العلوم /قسم الادلة الجنائية، م.د. لينا موسى كاظم جامعه واسط كلية العلوم قسم التحليلات المرضية
This work is licensed under a Creative Commons Attribution 4.0 International License.
